FGFR1c mAb effects on glucose tolerance and pancreatic islet cell mass.

<p>(A) Oral glucose tolerance test (OGTT) 15 d after repeated injections of either R1c mAb or control mAb in female or male DIO mice (<i>n</i> = 7–8, three i.p. injections 10 mg/kg on day 0, 7 and 14). Glucose and insulin area under the curve (AUC) were calculated. **<i>P</i><0.01 and ***<i>P</i><0.001 <i>vs.</i> respective control mAb, Mann Whitney <i>U</i>-test. (B) Representative pancreatic islet staining of insulin (green), glucagon (red), and nucleuses (blue), and (C) β and α cell quantification after repeated injections with either R1c mAb or control mAb in female DIO mice after 28 d treatment (<i>n</i> = 7, 10 mg/kg i.p. day 0, 7, 14 and 21). N.S. = Non Significant. (D) Percent body weight change after a single injection of R1c mAb in female DIO mice fed <i>ad libitum</i> (<i>ad lib</i>) or control mAb treated female DIO mice fed <i>ad lib</i> or pair-fed (pf) twice daily to match the food intake in R1c mAb treated female DIO mice fed <i>ad lib</i> (<i>n</i> = 6, 3 mg/kg s.c., indicated with an arrow). **<i>P</i><0.01 R1c mAb <i>ad lib vs.</i> control mAb <i>ad lib</i>, ^##<i>P</i><0.01 control mAb pf <i>vs.</i> control mAb <i>ad lib</i>, and ^§<i>P</i><0.05 R1c mAb <i>ad lib vs.</i> control mAb pf, Mann Whitney <i>U</i>-test. (E) Effects on 3 h fasting glucose levels before treatment start day 0 and after 4 d treatment. **<i>P</i><0.01 <i>vs.</i> Treatment day 0 within respective treatment group, Mann Whitney <i>U</i>-test. (F) Effects on 3 h fasting insulin levels after 4 d treatment. *<i>P</i><0.05, **<i>P</i><0.01 <i>vs.</i> Control mAb fed <i>ad lib</i>, Mann Whitney <i>U</i>-test. Values are means ± SEM.